retatrutide dosing clinical trial retatrutide dose escalation Reta data & — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP Retatrutide UK: 2026 Clinical Trial

Two-thirds of patients stopped taking the drugs within a year of starting them, according to one recent analysis of insurance claims

[8] Damm P, Houshmand-Oeregaard A, Kelstrup L, Lauenborg J, Mathiesen ER, Clausen TD

associate professor at Tufts University School of Medicine

A balanced diet, regular exercise and healthy lifestyle habits remain essential for sustainable results

Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: A systematic review and meta-analysis

A Systematic Review of Protein Intake and Muscle Mass in Resistance Training